Keywords: sanofi-aventis, withdraws, rimonabant, nda, emea, review, psychiatric

Sanofi-Aventis withdraws rimonabant NDA; EMEA to review psychiatric event data

Article | 09 July 2007

Print This

French drug major Sanofi-Aventis has decided to withdraw the US New Drug Application for its anti-obesity drug rimonabant. On the ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in